Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Rev Cardiovasc Med. 2010 Winter;11(1):26-32.

Pitavastatin: the newest HMG-CoA reductase inhibitor.

Author information

  • 1The David Geffen School of Medicine, UCLA Preventative Cardiology Program, University of California at Los Angeles, Los Angeles, CA, USA.

Abstract

Statins were first introduced in the 1980s as a treatment of hypercholesterolemia. They provide a remarkable array of clinical benefits, including the reduction of low-density lipoprotein cholesterol, total cholesterol, and triglycerides, and elevation of high-density lipoprotein cholesterol. The US Food and Drug Administration has recently approved a new statin-pitavastatin-for launch in 2010. In several clinical trials, pitavastatin has shown favorable clinical efficacy, a positive safety profile, and encouraging clinical experience in Japan and other parts of Asia.

PMID:
20495513
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk